- Open Access
Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma
SpringerPlus volume 5, Article number: 551 (2016)
To examine the predictive value of tumor markers for evaluating tumor resectability in patients with hilar cholangiocarcinoma and to explore the prognostic effect of various preoperative factors on resectability in patients with potentially resectable tumors. Patients with potentially resectable tumors judged by radiologic examination were included. The receiver operating characteristic (ROC) analysis was conducted to evaluate serum carbohydrate antigenic determinant 19-9 (CA 19-9), carbohydrate antigen 125 (CA 125) and carcino embryonie antigen levels on tumor resectability. Univariate and multivariate logistic regression models were also conducted to analysis the correlation of preoperative factors with resectability.
In patients with normal bilirubin levels, ROC curve analysis calculated the ideal CA 19-9 cut-off value of 203.96 U/ml in prediction of resectability, with a sensitivity of 83.7 %, specificity of 80 %, positive predictive value of 91.1 % and negative predictive value of 66.7 %. Meanwhile, the optimal cut-off value for CA 125 to predict resectability was 25.905 U/ml (sensitivity, 78.6 %; specificity, 67.5 %). In a multivariate logistic regression model, tumor size ≤3 cm (OR 4.149, 95 % CI 1.326–12.981, P = 0.015), preoperative CA 19-9 level ≤200 U/ml (OR 20.324, 95 % CI 6.509–63.467, P < 0.001), preoperative CA 125 levels ≤26 U/ml (OR 8.209, 95 % CI 2.624–25.677, P < 0.001) were independent determinants of resectability in patients diagnosed as hilar cholangiocarcinoma.
Preoperative CA 19-9 and CA 125 levels predict resectability in patients with radiological resectable hilar cholangiocarcinoma. Increased preoperative CA 19-9 levels and CA 125 levels are associated with poor resectability rate.
Hilar cholangiocarcinoma is a devastating malignant neoplasm with a poor prognosis and is generally diagnosed at an advanced stage (Baton et al. 2007; Xiong et al. 2015). Curative bile duct resection combined with hepatectomy, caudate lobectomy, lymph node dissection and even vascular resection and reconstruction represents the only curable method that can prolong the survival of patients diagnosed with hilar cholangiocarcinoma (Ramacciato et al. 2010; Hidalgo et al. 2008; Neuhaus et al. 2003; Miyazawa et al. 2006). However, hilar cholangiocarcinoma has the propensity of longitudinal diffusion along the bile duct mucosa, which makes the curative surgery difficult (Cheng et al. 2012). Moreover, hilar cholangiocarcinoma is located in a peculiar anatomic position and tends to invade major adjacent structures including the hepatic parenchyma, the caudate lobe, the portal vein, the hepatic artery and the peripheral nerve system, resulting in low resectability chances, high postoperative recurrence, and poor survival outcome (Saxena et al. 2011; Li et al. 2011; Ercolani et al. 2010; Burke et al. 1998). Some tumors are considered resectable in view of preoperative imaging evaluation. However, the intraoperative findings of biliary involvement and vascular invasion often do not match with the preoperative assessment. How to improve the predictive role of tumor resectability—is still a puzzled problem faced by surgeons. Curative resectability rate is usually very dismal (<40 %) and most of the patients are conducted palliatively (Saxena et al. 2011; Launois et al. 2000; Jarnagin et al. 2001, 2005).
Previous studies indicated serum tumor markers such as CA 19-9, CA 125 and CEA are important reference factors for the diagnosis and prognosis of gastrointestinal malignant neoplasms and are conventionally detected before and after surgery (Juntermanns et al. 2010; Wang et al. 2015). These serum tumor markers are also widely used in predicting the resectability of gastrointestinal malignancies (Luo et al. 2013; Brown et al. 2015). As for hilar cholangiocarcinoma, the clinical predictive value of these parameters remains indistinct and there is an ongoing debate about the validity of these tumor markers for hilar cholangiocarcinoma. In addition, the serum CA 19-9 level depends on the Lewis phenotype and about 5–14 % of the population is Lewis negative (Lea−b−), which was characterized by CA 19-9 nonsecretory (Chen et al. 2015; Liu et al. 2015; Cai et al. 2014). Patients with Lewis negative (Lea−b−) cannot secrete the CA 19-9 even when they possess a malignant tumor, which is associated with poor survival outcome even after curative resection. However, previous studies almost ignored this significant factor while analyzing the prognostic effect of preoperative serum CA 19-9 levels on hilar cholangiocarcinoma. Furthermore, previous studies did not consider the impact of obstructive jaundice and cholangitis on the serum CA 19-9 levels; as was reported in literature, almost all of patients with hilar cholangiocarcinoma have hyperbilirubinemia, obstructive jaundice and cholangitis in turn arouses an enhancement in preoperative serum CA 19-9 levels (Harder et al. 2007; Rerknimitr et al. 2013; Juntermanns et al. 2010). Meanwhile, there is also little knowledge about the predictive value of serum tumor markers such as CA 19-9, CA 125 and CEA for evaluating tumor resectability in patients with hilar cholangiocarcinoma and the prognostic effect of various preoperative tumor factors on tumor resectability is also unclear. Thus, the role of serum CA 19-9, CA 125 and CEA in evaluating resectability of hilar cholangiocarcinoma should be further studied.
Therefore, the current study was conducted to highlight following points: (1) to examine the utility of preoperative CA 19-9, CA 125 and CEA levels in predicting the resectability of patients with hilar cholangiocarcinoma using the ROC analysis, (2) to study the correlation of various preoperative factors with tumor resectability rate using univariate and multivariate analysis.
Patients and methods
A total of 471 patients with radiographically potential resectable hilar cholangiocarcinoma at West China Hospital of Sichuan University from 1995 to 2014 were included. Patients with ampullary carcinomas, gallbladder carcinomas, intrahepatic cholangiocarcinomas were excluded, patients with radiographically unresectable neoplasm at presentation, preoperative chemotherapy and radiotherapy, preoperative serum CA 19-9 levels <5 U/ml (CA 19-9 nonsecretory), cholangitis were also excluded. For resectable tumors, pathological examination of the resected specimen was conducted, and for unresectable tumors, intraoperative biopsy was implemented. All patients were histologically identified as hilar bile duct adenocarcinoma.
Before surgery, an elaborative medical history and physical exam was conducted in all patients, then the laboratory tests, the ultrasonography, the multi-detector row spiral CT, the magnetic resonance imaging were regularly detected. Preoperative biliary drainage was applied in patients with obstructive jaundice by endoscopic retrograde cholangiopancreatography (n = 142) and percutaneous transhepatic cholangiodrainage (n = 78). Patients were considered as unresectable if: (1) advanced bile duct infiltration that precludes intact tumor removal, (2) invasive of major vascular systems such as bilateral portal vein involvement that hampers vascular reconstruction, (3) lymph nodes metastases beyond the hepatoduodenal ligament, (4) unilateral hepatic lobe atrophy combined with invasion of contralateral portal vein or hepatic artery, (5) unilateral hepatic lobe atrophy combined with invasion of contralateral secondary biliary radicles, (6) unilateral secondary biliary radicles involvement combined with invasion of contralateral portal vein or hepatic artery, (7) pathology confirmed hilar cholangiocarcinoma with evidence of distant metastases (Dumitrascu et al. 2013). All the operations were conducted by experienced surgeons in our center.
The demographics, clinical data, laboratory data, operating details and survival outcomes were documented in detail. Serum CA 19-9, CA 125 and CEA levels were calculated by Roche chemiluminescence immunoassay method. Preoperative serum CA 19-9, CA 125, CEA levels were assayed just before the surgery so as to avert the influence of obstructive jaundice. Tumor size was determined as the largest dimension based on preoperative imaging test. Patients with negative margins (R0 resection) and microscopically positive margins (R1 resection) were defined as resectable, while those with macroscopically positive margins (R2 resection) and palliative surgery were considered as unresectable. Patients were then further sub-divided into two groups: patients with preoperative hyperbilirubinemia (n = 333) and patients with normal range of serum bilirubin levels (n = 138).
As hilar cholangiocarcinoma is a devastating malignant disease, all patients were rigorously monitored and followed-up in outpatient clinics. All enrolled patients were assessed every 2–3 months with the basic measurement of tumor markers, liver functions, ultrasonography in the first year after surgery, and then 3–6 months annually thereafter. For those underwent curative surgery, if suspected as recurrence or distant metastasis, computed tomography or magnetic resonance imaging test was further conducted.
Patient characteristics were expressed using frequency or descriptive analysis. The linear regression model was conducted to examine the relationship between CA 19-9, CA 125, CEA and the preoperative total bilirubin levels. The receiver operating characteristic (ROC) curve analysis was used both in the whole group (n = 471) and in the subgroup with normal range of serum total bilirubin levels (n = 138) to analyze the prognostic effect of CA 19-9, CA 125, CEA on tumor resectability and the best cut-off values of CA 19-9, CA 125 and CEA. Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) were computed for each cut-off point of CA 19-9, CA 125 and CEA. Univariate and multivariate logistic regression models were also performed to check the independent factors correlated with resectability of these patients. The P value <0.05 was deemed as significant. The Statistical analysis was presented using the SPSS version 16.0 (SPSS Inc. Chicago, IL, USA).
Demographic and clinical characteristics
Although 471 patients with hilar bile duct carcinoma appeared to have potentially resectable tumors in the light of the preoperative imaging examinations, only 309 of them (65.6 %) were operated on with curative surgery; which included hilar bile duct resection (45 cases), left hemihepatectomy (118 cases), right hemihepatectomy (86 cases), left trisegmentectomy (34 cases), right trisegmentectomy (13 cases), and mesohepatetctomy (13 cases). Caudate lobe was conventionally removed (251 cases), except for some earlier cases of type I papillary carcinoma. The other 162 patients were identified as unresectable due to tumors widely involving bilateral intrahepatic bile ducts or bilateral portal vein involvement or distant lymph nodes metastases or peritoneal metastases. The median CEA, CA 125, and CA 19-9 levels for all patients were 3.37 ng/ml, 22.5 and 199 U/ml, respectively. In those with normal range of serum bilirubin levels, the resectability rate was 71 % (n = 98; 11, hilar bile duct resection; 46, left hemihepatectomy; 30, right hemihepatectomy; 6, left trisegmentectomy; 3, right trisegmentectomy; 2, mesohepatetctomy), and the median CEA, CA 125, CA 19-9 levels for patients with normal bilirubin levels were 2.65 ng/ml, 22.0 and 155.8 U/ml, respectively; The clinical characteristics of the selected patients are lined out in Table 1.
In all patients, a positive relevance was detected between preoperative serum CA 19-9 and total bilirubin level (r = 0.180, P = 0.012), but not in CEA (r = 0.103, P = 0.149) and CA 125 (r = 0.103, P = 0.149).
Then we further analyzed the survival outcome of patients with or without resectable tumors, The median follow-up time was 19 months (range 1–90 months). In resected group, the median overall survival time was 36.8 months and the 1, 3, 5 year survival rates were 83, 51, and 30 %, respectively, while in patients with unresectable diseases, the median overall survival time was 7.9 months and the 1, 3, 5 year survival rates were 28, 0, and 0 %, respectively (Fig. 1, P < 0.001).
In the whole patients group (Table 2; Fig. 2), ROC analysis determined that the preoperative CA 19-9 cut-off value of 200.4 U/ml yielded a sensitivity of 71.2 %, specificity of 88.3 %, PPV of 92.1 %, NPV of 61.6 % in predicting resectability. In addition, a cut-off value of 26.84 U/ml for CA 125 also resulted in a sensitivity, specificity, PPV and NPV of 77, 71, 83.2 and 61.6 % for prediction of resectability respectively; Furthermore, in order to eliminate the impact of hyperbilirubinemia on CA 19-9 level, we then conducted ROC analysis in those with normal bilirubin levels (Table 2). We estimated the ideal CA 19-9 cut-off value of 203.96 U/ml in prediction of resectability, with a sensitivity of 83.7 %, specificity of 80 %, PPV of 91.1 % and NPV of 66.7 % (Fig. 3); meanwhile, the optimal cut-off value for CA 125 to predict resectability was 25.905 U/ml (sensitivity, 78.6 %; specificity, 67.5 %).
Uni- and multivariate analysis the correlation of preoperative factors with resectability
The relationship of resectability rate with various preoperative tumor characteristics are presented in Table 3. In those with preoperative normal bilirubin levels, a significantly increased rate of preoperative CA 19-9 level >200 U/ml was observed in unresectable group compared with resected group (83.7 vs 16.3 %, P < 0.001). In addition, patients with preoperative CA 125 level >26 U/ml had a decreased resectability rate of 21.4 % in comparison with 78.6 % of those with lower CA 125 levels (P < 0.001). Meanwhile, the type 3 and 4 of Bismuth–Corlette classification also conferred to a poor resectability rate (37.8 %) when compared with type 1 and 2 (P = 0.017); Moreover, patients with BMI (body mass index) lower than the median value were also associated increased resectability (P = 0.03). Increased resectability was also witnessed in patients with preoperative tumor size ≤3 cm compared with tumor size >3 cm (P < 0.001).
To estimate the independent contributing determinants to the resectability, a multivariate logistic regression model was carried out and factors significant in the univariate analysis were all involved in (Table 4). It indicated that tumor size ≤3 cm (OR 4.149, 95 % CI 1.326–12.981, P = 0.015), preoperative CA 19-9 level ≤200 U/ml (OR 20.324, 95 % CI 6.509–63.467, P < 0.001), preoperative CA 125 levels ≤26 U/ml (OR 8.209, 95 % CI 2.624–25.677, P < 0.001) were independent determinants of resectability in patients diagnosed as hilar cholangiocarcinoma.
Hilar cholangiocarcinoma is still a technically challenging operation characterized by low resectability rate, high postoperative recurrence, and poor survival outcome. Due to technologic progresses in preoperative imaging, much experience has been gained in preoperative assessment of the stage and aggressiveness of hilar bile duct tumors. However, many patients are still characterized as radiologically resectable tumors and undergo unnecessary laparotomy, only to be found to have advanced diseases such as tumors widely involving bilateral intrahepatic bile ducts or bilateral portal vein involvement or distant lymph nodes metastases or small peritoneal metastases that preclude curative resection. Hence, simple and practical methods like preoperative tumor marker evaluations are badly demanded to act as a complementary instrument to the preoperative imaging estimate for assessing the resectability of hilar cholangiocarcinoma so as to provide an additional reference and guideline for treatment of hilar cholangiocarcinoma.
CA 19-9, CEA, CA 125 are the most investigated tumor markers that have been appraised for preoperative diagnosis and postoperative prognosis in patients with hilar cholangiocarcinoma. Increased CA 19-9, CEA levels have been reported to be associated with advanced tumor stage and poor survival outcome (Juntermanns et al. 2010). Moreover, the two tumor markers were also widely used in the diagnosis of hilar cholangiocarcinoma (Rerknimitr et al. 2013; Soares et al. 2014; Nakeeb et al. 1996; Patel et al. 2000; Qin et al. 2004). Meanwhile, the dynamics of tumor markers are routinely detected as a measurement of recurrence and method to predict the disease process. Significantly elevated postoperative CA 19-9 level was associated with early recurrence (LaFemina and Jarnagin 2012). Nevertheless, little is known about the impact of these tumor markers on resectability of hilar cholangiocarcinoma.
In our current study, we demonstrated serum CA 19-9 was a predictor of resectability with an area under the curve (AUC) of 0.825, and the optimal cut-off value was 203.96 U/ml. Different from many previous studies, these results were not affected by hyperbilirubinemia and cholangitis, which was covered to have positive enhancement in CA 19-9 levels and was re-identified here—a positive relevance (r = 0.180, P = 0.012) was detected between preoperative serum CA 19-9 and total bilirubin level (Rerknimitr et al. 2013; Harder et al. 2007; Katz et al. 2010). In addition, patients with CA 19-9 nonsecretory were also excluded. Even in the total patients group (n = 471), which patients with hyperbilirubinemia were included, the preoperative CA 19-9 levels could also predict resectability with an AUC of 0.815. Furthermore, we conducted univariate and multivariate models to better estimate the predictive role of preoperative CA 19-9 with tumor resectability using the 200 U/ml cut-off point (to consistent with the ROC results). Patients with resected disease obviously had preoperative CA 19-9 lesser than 200 U/ml and CA 19-9 was also identified as an independent factor to be associated with tumor resectability. Thus, in consideration of the noteworthy predict value of CA 19-9 on resectability, it may act as a complementary tool to the preoperative imaging study so as to precisely predict the resectability of hilar cholangiocarcinoma and avoid unnecessary surgical attack.
Notably, enhanced preoperative CA 125 level was also correlated with decreased tumor resectability in hilar bile duct carcinoma in current series, as CA 125 is noted to be a momentous factor in detection and management of ovarian cancer (Chen et al. 2015). Besides, CA 125 also has prognostic effect on pancreatic cancer and can also predict the resectability (Chen et al. 2014; Luo et al. 2013; Gu et al. 2015). However, no previous studies have specifically discussed the predictive value of CA 125 on resectability of hilar cholangiocarcinoma. In the present study, CA 125 was not associated with hyperbilirubinemia and cholangitis. In the whole patients group, an AUC of 0.785 was identified and a best cut-off value of 26.84 U/ml was also obtained. Even in patients with normal bilirubin level, the CA 125 remained predictive of resectability with an AUC of 0.730 and a optimal cut-off value of 25.9 U/ml. The predictive value of CA 125 was definitely lower than the CA 19-9. Using the cut-off point of 26 U/mL, patients with CA 125 levels larger than 26 U/ml were significantly correlated with lower resectability as was confirmed in the multivariate regression model in current study. Thus, together with CA 19-9, the CA 125 should be preoperatively analyzed and regarded as a supplementary kit to make up for the defection of preoperative imaging test in predicting the resectability and better guide the treatment.
The relationship of CEA and resectability was also analyzed. In patients with normal bilirubin levels, ROC analysis determined that the preoperative CEA cut-off value of 4.37 ng/ml yielded a sensitivity of 60.2 % and specificity of 45 % in predicting the resectability. In the univariate and multivariate logistic analysis, the CEA level was not a reliable factor associated with resectability. Thus, the predictive value of CEA on tumor resectability was less than CA 19-9 and CA 125.
In addition, tumor size was also carefully examined and it was associated with tumor resectability. Patients with tumor size >3 cm were more likely to possess an unresectable tumor. It has been universally acknowledged that patients with resectable disease undoubtedly have preferable survival outcome and was re-confirmed in this series (Dumitrascu et al. 2013; Dinant et al. 2006; Lee et al. 2010). In present study, we used the tumor size collected from preoperative imaging findings, as post-operative pathological tumor size finding was difficult to evaluate in cases of unresectable tumors and it depends on the experience of the surgeons, which may induce a bias. Thus, in view that the 3 cm cut-off point could affect the resectability, we may conclude that tumor size was also an important prognostic factor. On the other hand, the 3 cm cut-off also identified the usefulness of the current T stage of DeOliveira staging system, in which the 3 cm cut-off was characterized as T3 (Deoliveira et al. 2011; Regimbeau et al. 2014), patients with T3 tumors are not eligible for liver transplantation and have a high tendency of accompanying with poor outcome (Chaiteerakij et al. 2014; Hassoun et al. 2002; Darwish Murad et al. 2012). In addition, the T3 tumors frequently invade the major vascular tissues, the caudate lobe, and the peripheral nerve system and make the resection extraordinary difficult and more often than not, patients in this situation have unresectable disease as was confirmed here. Thus, the preoperative tumor size should also be taken into account to better judge the resectability.
Under most circumstances, it is unpractical to employ a single biomarker to forecast the resectability of hilar cholangiocarcinoma. Tumor biomarkers should act as complementary instrument to the preoperative imaging evaluation, and a comprehensive combination of clinical manifestation, preoperative imaging scan and other prognostic factors including the tumor size are urgently warranted so as to better assess the resectability of hilar cholangiocarcinoma and provide a pivotal reference and guideline for treatment of hilar cholangiocarcinoma.
Our study has limitations inherent to its retrospective study design. Moreover, hilar cholangiocarcinoma is generally diagnosed at an advanced stage and many patients are with hyperbilirubinemia. Thus, patients with normal bilirubin levels are relatively less. Therefore, further research and multi-center studies are clearly warranted to support clinically usefulness of the present finding.
In conclusion, Preoperative CA 19-9 and CA 125 levels predict resectability in patients with radiological resectable hilar cholangiocarcinoma. Increasing preoperative CA 19-9 levels and CA 125 levels are associated with poor resectability rate, which may act as auxiliary indexes for assessing the resectability of hilar cholangiocarcinoma.
receiver operating characteristic analysis
- CA 19-9:
carbohydrate antigenic determinant 19-9
- CA 125:
carbohydrate antigen 125
carcino embryonie antigen
positive predictive value
negative predictive value
areas under the curve
Baton O, Azoulay D, Adam DV, Castaing D (2007) Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg 204(2):250–260. doi:10.1016/j.jamcollsurg.2006.10.028
Brown EG, Canter RJ, Bold RJ (2015) Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. J Surg Oncol 111(3):293–298. doi:10.1002/jso.23812
Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH (1998) Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228(3):385–394
Cai WK, Lin JJ, He GH, Wang H, Lu JH, Yang GS (2014) Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol 7(11):7890–7898
Chaiteerakij R, Harmsen WS, Marrero CR, Aboelsoud MM, Ndzengue A, Kaiya J, Therneau TM, Sanchez W, Gores GJ, Roberts LR (2014) A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol 109(12):1881–1890. doi:10.1038/ajg.2014.327
Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, Jin CH, Yang YT, Feng XS (2014) Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys. doi:10.1007/s12013-014-0345-2
Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ (2015) Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine 94(19):e751. doi:10.1097/MD.0000000000000751
Cheng QB, Yi B, Wang JH, Jiang XQ, Luo XJ, Liu C, Ran RZ, Yan PN, Zhang BH (2012) Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 38(12):1197–1203. doi:10.1016/j.ejso.2012.08.009
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1):88–98. doi:10.1053/j.gastro.2012.04.008 (e83; quiz e14)
Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA (2011) New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53(4):1363–1371. doi:10.1002/hep.24227
Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM (2006) Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol 13(6):872–880. doi:10.1245/ASO.2006.05.053
Dumitrascu T, Chirita D, Ionescu M, Popescu I (2013) Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg 17(5):913–924. doi:10.1007/s11605-013-2144-2
Ercolani G, Zanello M, Grazi GL, Cescon M, Ravaioli M, Del Gaudio M, Vetrone G, Cucchetti A, Brandi G, Ramacciato G, Pinna AD (2010) Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. J Hepatobiliary Pancreat Sci 17(3):329–337. doi:10.1007/s00534-009-0249-5
Gu YL, Lan C, Pei H, Yang SN, Liu YF, Xiao LL (2015) Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pac J Cancer Prev 16(15):6569–6573. doi:10.7314/apjcp.2015.16.15.6569
Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O (2007) Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomark Prev 16(10):2097–2100. doi:10.1158/1055-9965.EPI-07-0155
Hassoun Z, Gores GJ, Rosen CB (2002) Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am 11(4):909–921
Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ, Prasad KR, Lodge JP (2008) Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 34(7):787–794. doi:10.1016/j.ejso.2007.10.005
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–509)
Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, DeMatteo RP, D’Angelica M, Koea J, Blumgart LH (2005) Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241(5):703–714. doi:10.1097/01.sla.0000160817.94472.fd
Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, Trarbach T, Paul A, Kaiser GM (2010) Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res 15(8):357–361
Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB (2010) Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17(7):1794–1801. doi:10.1245/s10434-010-0943-1
LaFemina J, Jarnagin WR (2012) Surgical management of proximal bile duct cancers. Langenbecks Arch Surg 397(6):869–879. doi:10.1007/s00423-012-0928-6
Launois B, Reding R, Lebeau G, Buard JL (2000) Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 7(2):128–134. doi:10.1007/s005340000070128.534
Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY (2010) Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 17(4):476–489. doi:10.1007/s00534-009-0204-5
Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q (2011) Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg 28(3):226–231. doi:10.1159/000327361
Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J, Guha S, Fu D, Ni Q, Jatoi A, Chari S, McCleary-Wheeler AL, Fernandez-Zapico ME, Li M, Yu X (2015) A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer 136(9):2216–2227. doi:10.1002/ijc.29242
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q, Yu X (2013) CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg 17(12):2092–2098. doi:10.1007/s11605-013-2389-9
Miyazawa M, Toshimitsu Y, Torii T, Okada K, Koyama I (2006) Extended right hepatectomy for hilar cholangiocarcinoma with resection of the left hepatic duct prior to hepatic resection. J Surg Oncol 93(1):72–75. doi:10.1002/jso.20401
Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, Pitt HA (1996) Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 171(1):147–152. doi:10.1016/S0002-9610(99)80090-7 (discussion 152–143)
Neuhaus P, Jonas S, Settmacher U, Thelen A, Benckert C, Lopez-Hanninen E, Hintze RE (2003) Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 388(3):194–200. doi:10.1007/s00423-003-0383-5
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207
Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004) Utility of serum CA 19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 10(3):427–432
Ramacciato G, Nigri G, Bellagamba R, Petrucciani N, Ravaioli M, Cescon M, Del Gaudio M, Ercolani G, Di Benedetto F, Cautero N, Quintini C, Cucchetti A, Lauro A, Miller C, Pinna AD (2010) Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg 76(11):1260–1268
Regimbeau JM, Fuks D, Pessaux P, Bachellier P, Chatelain D, Diouf M, Raventos A, Mantion G, Gigot JF, Chiche L, Pascal G, Azoulay D, Laurent A, Letoublon C, Boleslawski E, Rivoire M, Mabrut JY, Adham M, Le Treut YP, Delpero JR, Navarro F, Ayav A, Boudjema K, Nuzzo G, Scotte M, Farges O (2014) Tumour size over 3 cm predicts poor short-term outcomes after major liver resection for hilar cholangiocarcinoma. By the HC-AFC-2009 group. HPB. doi:10.1111/hpb.12296
Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, Seo DW, Pantongrag-Brown L, Sangchan A, Pisespongsa P, Akaraviputh T, Reddy ND, Maydeo A, Itoi T, Pausawasdi N, Punamiya S, Attasaranya S, Devereaux B, Ramchandani M, Goh KL, Asia-Pacific Working Group on Hepatobiliary C (2013) Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 28(4):593–607. doi:10.1111/jgh.12128
Saxena A, Chua TC, Chu FC, Morris DL (2011) Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg 202(3):310–320. doi:10.1016/j.amjsurg.2010.08.041
Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM (2014) Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr 3(1):18–34. doi:10.3978/j.issn.2304-3881.2014.02.05
Wang Y-Y, Zhong J-H, Lu Z, Qin H-G, Li L-Q (2015) Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma? Tumor Biol. doi:10.1007/s13277-015-4326-x
Xiong J, Nunes QM, Huang W, Wei A, Ke N, Mai G, Liu X, Hu W (2015) Major hepatectomy in Bismuth types I and II hilar cholangiocarcinoma. J Surg Res 194(1):194–201. doi:10.1016/j.jss.2014.10.029
HJH contributed to the analysis and drafted the manuscript. WJM, JKW and QY contributed to data acquisition and analyzed the manuscript. AS, NSC and YQT were involved in the revision of the manuscript. FYL and HM contributed to the study design and revision of the manuscript. All authors read and approved the final manuscript.
The authors acknowledge the financial support from National Nature Science of China (30801111, 30972923) and Science & Technology Support Project of Sichuan Province (No. 2014SZ0002-10).
The authors declare that they have no competing interests.
Our research has been approved by the ethics committee of the West China Hospital of Sichuan University and that all subjects gave their consent to participate in this study. All involved patients (alive) gave their informed consent statement prior to the study inclusion. Our manuscript has not been assessed scientifically by others yet.
Hai-Jie Hu and Hui Mao contributed equally to this manuscript
About this article
Cite this article
Hu, HJ., Mao, H., Tan, YQ. et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. SpringerPlus 5, 551 (2016). https://doi.org/10.1186/s40064-016-2181-x
- Hilar cholangiocarcinoma
- Carbohydrate antigen 19-9 (CA 19-9)
- Carbohydrate antigen 125 (CA 125)